Limits...
Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report.

Niccoli L, Cassarà E, Kaloudi O, Nannini C, Romagnoli M, Cantini F - BMC Musculoskelet Disord (2015)

Bottom Line: Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.This case suggests new perspectives for the treatment of asbestosis and its systemic features.

View Article: PubMed Central - PubMed

Affiliation: Consultant in Rheumatology, Rheumatology Division, Hospital of Prato, Prato, Italy. lniccoli64@gmail.com.

ABSTRACT

Background: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.

Case presentation: We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.

Conclusion: This case suggests new perspectives for the treatment of asbestosis and its systemic features.

No MeSH data available.


Related in: MedlinePlus

Thoracic HRCT. Pleural thickening and fibrosis
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4465479&req=5

Fig3: Thoracic HRCT. Pleural thickening and fibrosis

Mentions: HRCT of the lung showed pulmonary fibrosis with pleural plaques suggesting asbestosis (Figs. 1, 2 and 3).Fig. 1


Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report.

Niccoli L, Cassarà E, Kaloudi O, Nannini C, Romagnoli M, Cantini F - BMC Musculoskelet Disord (2015)

Thoracic HRCT. Pleural thickening and fibrosis
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4465479&req=5

Fig3: Thoracic HRCT. Pleural thickening and fibrosis
Mentions: HRCT of the lung showed pulmonary fibrosis with pleural plaques suggesting asbestosis (Figs. 1, 2 and 3).Fig. 1

Bottom Line: Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.This case suggests new perspectives for the treatment of asbestosis and its systemic features.

View Article: PubMed Central - PubMed

Affiliation: Consultant in Rheumatology, Rheumatology Division, Hospital of Prato, Prato, Italy. lniccoli64@gmail.com.

ABSTRACT

Background: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.

Case presentation: We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.

Conclusion: This case suggests new perspectives for the treatment of asbestosis and its systemic features.

No MeSH data available.


Related in: MedlinePlus